Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Zydus Cadila and Prolong team up on next-gen protein
February 2008
SHARING OPTIONS:

AHMEDABAD, India—Global pharmaceutical company Zydus Cadila, and Prolong Pharmaceuticals Inc., a Monmouth Junction, N.J.-based, venture-backed drug delivery research and development company, have announced a collaboration for the development of a next-generation therapeutic protein, PEG-EPO, for the treatment of severe anemia.
The Zydus-Prolong pact seeks to increase productivity in the drug development of this protein by leveraging the combined strengths of both companies. As per the agreement, both companies will utilize Prolong's differentiated PEGylation technology to make PEG-EPO. Zydus Cadila will leverage its expertise in carrying out a focused drug development program, including candidate selection, filing of the investigational new drug, undertaking preclinical studies and human clinical trials and marketing it in mutually agreed upon territories globally. This joint development will help in developing an optimized drug candidate with improved therapeutic properties. Both partners expect to equitably share risk and reward for this program.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.